The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study

Sertraline is known to undergo changes in pharmacokinetics during pregnancy. CYP 2C19 has been implicated the interindividual variation clinical effect associated with sertraline activity. However, knowledge of suitable dose titrations pregnancy and within phenotypes lacking. A pharmacokinetic modeling virtual trials approach was implemented to: (i) assess gestational trough plasma concentrations for phenotypes, (ii) identify appropriate titration strategies stabilize levels a defined therapeutic range throughout gestation. decreased gestation, maternal volume expansion reduction albumin being identified as possible causative reasons. All required increase For extensive metabolizer (EM) ultrarapid (UM) doses 100–150 mg daily are poor metabolizers (PM), 50 trimester 1 followed by 100 trimesters 2 3 required.